PhaseRx Inc (PZRX.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2008||Independent Chairman of the Board|
|61||2017||President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director|
|2015||Vice President - Chemistry|
|2015||Vice President - Biology|
|57||2016||Chief Medical Officer|
- BRIEF-PhaseRx Receives Decision From Nasdaq Hearings Panel For Continued Listing Of Shares
- BRIEF-Phaserx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding
- BRIEF-PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from EMA
- BRIEF-PhaseRx reports Q3 loss per share $0.23
- BRIEF-Phaserx gets delisting notice from NASDAQ